Summit Therapeutics's total assets for Q3 2024 were $502.85M, an increase of 47.09% from the previous quarter. SMMT total liabilities were $64.93M for the fiscal quarter, a -55.76% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.